Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 4/20 | 0.62 |
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.52 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156504 | 1.00 | IP6K1 (0.62) | IP6K1CTSVCTSLELANEKDM1A | |
| Hydrochloric Acid SCHEMBL27988350 | 0.99 | IP6K1 (0.60) | IP6K1CTSVCTSLELANEKDM1A | |
| SCHEMBL20897397 | 0.94 | IP6K1 (0.69) | IP6K1CTSVCTSLELANEIP6K3 | |
| SCHEMBL1781759 | 0.92 | IP6K1 (0.58) | IP6K1CTSVCTSLELANEKDM1A | |
| SCHEMBL7206263 | 0.89 | KDR (0.50) | IP6K1CTSVCTSLELANEKDM1A | |
| SCHEMBL14520678 | 0.86 | IP6K1 (0.63) | IP6K1IP6K3IP6K2LMNAHTT | |
| SCHEMBL4226040 | 0.86 | IP6K1 (0.57) | IP6K1CTSVCTSLELANEKDM1A | |
| SCHEMBL3528857 | 0.85 | KDM1A (0.53) | IP6K1CTSVCTSLELANEKDM1A | |
| SCHEMBL8917 | 0.84 | SRC (0.63) | IP6K1IP6K3IP6K2EGFRKDM4E | |
| SCHEMBL17165598 | 0.84 | IP6K1 (0.63) | IP6K1CTSVCTSLKDM1AIP6K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9617227-B2 | Process of preparing a quinazoline derivative | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2017-04-11 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008020302-A2 | HETEROAROMATIC QUINOLINE-BASED COMPOUNDS AS PHOSPHODIESTERASE (PDE) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1384712-B1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BREWERY (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | IP6K1 267/4885CTSV 4047/4885CTSL 4275/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | IP6K1 267/4885CTSV 4047/4885CTSL 4275/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | IP6K1 267/4885CTSV 4047/4885CTSL 4275/4885 |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | CYTH3, NQO2, NRAS | IP6K1 2604/4885CTSV 98/4885CTSL 12/4885 |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | IP6K1 267/4885CTSV 4047/4885CTSL 4275/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | IP6K1 1985/4885CTSV 97/4885CTSL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.